Published in Int Urogynecol J Pelvic Floor Dysfunct on September 20, 2008
Complications of vaginal mesh: our experience. Int Urogynecol J Pelvic Floor Dysfunct (2009) 1.71
Surgical management of mesh-related complications after prior pelvic floor reconstructive surgery with mesh. Int Urogynecol J (2011) 1.52
Mesh removal following transvaginal mesh placement: a case series of 104 operations. Int Urogynecol J (2010) 1.25
Surgical management of lower urinary mesh perforation after mid-urethral polypropylene mesh sling: mesh excision, urinary tract reconstruction and concomitant pubovaginal sling with autologous rectus fascia. Int Urogynecol J (2013) 1.03
Recognition and management of nonrelaxing pelvic floor dysfunction. Mayo Clin Proc (2012) 0.96
Mesh-related and intraoperative complications of pelvic organ prolapse repair. Cent European J Urol (2014) 0.87
Symptom resolution after operative management of complications from transvaginal mesh. Obstet Gynecol (2014) 0.85
High risk of complications with a single incision pelvic floor repair kit: results of a retrospective case series. Int Urogynecol J (2013) 0.78
Computer modeling informs study design: vaginal estrogen to prevent mesh erosion after different routes of prolapse surgery. Int Urogynecol J (2012) 0.75
Reoperations for mesh-related complications after pelvic organ prolapse repair: 8-year experience at a tertiary referral center. Int Urogynecol J (2017) 0.75
Beyond the complications: medium-term anatomical, sexual and functional outcomes following removal of trocar-guided transvaginal mesh. A retrospective cohort study. Int Urogynecol J (2012) 0.75
Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol (1997) 16.86
Anterior colporrhaphy: a randomized trial of three surgical techniques. Am J Obstet Gynecol (2001) 2.76
Retrospective multicentre study of the new minimally invasive mesh repair devices for pelvic organ prolapse. BJOG (2008) 2.53
Functional and anatomical outcome of anterior and posterior vaginal prolapse repair with prolene mesh. BJOG (2005) 2.44
Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. Am J Obstet Gynecol (2001) 2.31
Transvaginal repair of genital prolapse: preliminary results of a new tension-free vaginal mesh (Prolift technique)--a case series multicentric study. Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.98
Vesicovaginal fistula and mesh erosion after Perigee (transobturator polypropylene mesh anterior repair). Urology (2006) 1.63
Surgical management of anterior vaginal wall prolapse: an evidencebased literature review. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.55
Midterm follow-up of high-grade genital prolapse repair by the trans-obturator and infracoccygeal hammock procedure after hysterectomy. Eur Urol (2006) 1.49
Risk factors for mesh erosion after transvaginal surgery using polypropylene (Atrium) or composite polypropylene/polyglactin 910 (Vypro II) mesh. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.47
[Changing attitudes on the surgical treatment of urogenital prolapse: birth of the tension-free vaginal mesh]. J Gynecol Obstet Biol Reprod (Paris) (2004) 1.38
Follow-up after polypropylene mesh repair of anterior and posterior compartments in patients with recurrent prolapse. Int Urogynecol J Pelvic Floor Dysfunct (2007) 1.36
Prolapse repair by vaginal route using a new protected low-weight polypropylene mesh: 1-year functional and anatomical outcome in a prospective multicentre study. Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.29
A randomized controlled trial comparing fascia lata and synthetic mesh for sacral colpopexy. Obstet Gynecol (2005) 1.18
Perioperative morbidity using transvaginal mesh in pelvic organ prolapse repair. Obstet Gynecol (2007) 1.05
Surgical management of posterior vaginal wall prolapse: an evidence-based literature review. Int Urogynecol J Pelvic Floor Dysfunct (2005) 0.93
Occurrence of postoperative hematomas after prolapse repair using a mesh augmentation system. Obstet Gynecol (2007) 0.88
Prevalence and outcomes of continence surgery in community dwelling women. J Urol (2003) 0.87
Retrovesical haematoma after anterior Prolift procedure for cystocele correction. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.85
Retroperitoneal hemorrhage after a vaginal mesh prolapse procedure. Obstet Gynecol (2007) 0.85
Histologic response of porcine collagen-coated and uncoated polypropylene grafts in a rabbit vagina model. Am J Obstet Gynecol (2008) 0.84
Pelvic arterial embolization in the setting of acute hemorrhage as a result of the anterior Prolift procedure. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.80
Dyspareunia and mesh erosion after vaginal mesh placement with a kit procedure. Obstet Gynecol (2008) 0.77
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
Update of AUA guideline on the surgical management of female stress urinary incontinence. J Urol (2010) 2.43
Use of bone anchors in surgery for stress urinary incontinence: pro. Urology (2004) 1.39
Large urethral prolapse formation after calcium hydroxylapatite (Coaptite) injection. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.90
Pelvic organ prolapse and the lower urinary tract: the relationship of vaginal prolapse to stress urinary incontinence. Curr Urol Rep (2005) 0.88
Bladder outlet obstruction in women: iatrogenic, anatomic, and neurogenic. Curr Urol Rep (2006) 0.88
Complications of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in men with stress urinary incontinence. Urology (2008) 0.87
De novo urge syndrome and detrusor instability after anti-incontinence surgery: current concepts, evaluation, and treatment. Curr Urol Rep (2002) 0.85
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int (2006) 0.82
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Clin Pharmacokinet (2004) 0.82
Beyond collagen: injectable therapies for the treatment of female stress urinary incontinence in the new millennium. Urol Clin North Am (2002) 0.81
Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int (2005) 0.81
Baseline abdominal pressure and valsalva leak point pressures-correlation with clinical and urodynamic data. Neurourol Urodyn (2003) 0.80
Selecting a medical therapy for overactive bladder. Rev Urol (2002) 0.78
Advancements in minimally invasive treatments for female stress urinary incontinence: radiofrequency and bulking agents. Curr Urol Rep (2003) 0.78
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J (2010) 0.77
Nonsurgical transurethral radiofrequency treatment of stress urinary incontinence in women. Womens Health (Lond Engl) (2007) 0.77
Current trends in the evaluation and management of female urinary incontinence. CMAJ (2006) 0.77
Impaired detrusor contractility: anything new? Curr Urol Rep (2002) 0.77
Post hoc interpretation of urodynamic evaluation is qualitatively different than interpretation at the time of urodynamic study. Neurourol Urodyn (2009) 0.77
Pharmacologic treatment for detrusor overactivity. Curr Urol Rep (2002) 0.76
Transobturator tape, bladder perforation, and paravaginal defect: a case report. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.75
Complications of Tegress injections. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.75
Overactive bladder in special patient populations. Rev Urol (2003) 0.75
Oxybutynin: an overview of the available formulations. Ther Clin Risk Manag (2006) 0.75
Female urology: the changing realm of diagnosis and management. J Urol (2006) 0.75
A case for botulinum toxin-A in idiopathic bladder overactivity. Curr Urol Rep (2004) 0.75
Functional brain imaging and the bladder: new insights into cerebral control over micturition. Curr Urol Rep (2003) 0.75
Female neurogenic vesicourethral dysfunction: evaluation and management. Curr Urol Rep (2005) 0.75
Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial. Curr Urol Rep (2002) 0.75
Surgical management of overactive bladder. Curr Urol Rep (2002) 0.75
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.75
Does uroflow predict ISD? Neurourol Urodyn (2008) 0.75
The emergence of new drugs for overactive bladder. Expert Opin Emerg Drugs (2006) 0.75
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. Curr Urol Rep (2006) 0.75
Clinical evaluation of women with lower urinary tract dysfunction. Clin Obstet Gynecol (2004) 0.75
Functional obstructed voiding in the neurologically normal patient. Curr Urol Rep (2006) 0.75